Does Blue Cross Blue Shield of North Carolina Cover Mounjaro?
The verdict
Conditional on most plans
Blue Cross Blue Shield of North Carolina covers Mounjaro for type 2 diabetes with prior authorization across commercial, ACA, Medicare Part D, and NC Medicaid lines. Mounjaro is not covered for weight loss. NC Medicaid removed weight-loss GLP-1s on 10/1/2025 and reinstated them on 12/19/2025 (Wegovy preferred) — but that churn affected only the on-label weight-loss products, not Mounjaro, which is diabetes-only. The weight-loss tirzepatide is Zepbound, with separate coverage.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield of North Carolina using your member ID.
Key facts
NC Medicaid removed weight-loss GLP-1s on 10/1/2025 and reinstated them on 12/19/2025 (Wegovy preferred). That churn applied only to on-label weight-loss products — Mounjaro is diabetes-only and its NC Medicaid T2D coverage was never interrupted.
NC Medicaid Preferred Drug List update, NC Department of Health and Human Services, 2025
The 2026 Medicare Part D out-of-pocket cap is $2,100. Most BCBS NC Part D enrollees on Mounjaro for T2D reach this cap within 2–3 months and pay $0 for the remainder of the year.
CMS.gov, Medicare Part D Redesign 2025–2026
The IRA-negotiated Medicare MFN price for tirzepatide (Mounjaro) is $245/month, effective mid-2026 for Medicare enrollees.
CMS.gov, IRA Drug Price Negotiation Program, 2026
Medicare vs. commercial coverage
Whether Blue Cross Blue Shield of North Carolina covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
BCBS NC Medicare Part D plans cover Mounjaro for type 2 diabetes only — not weight loss — with prior authorization. The 2026 Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach it within 2–3 months and pay $0 thereafter. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027), which covers weight-loss-approved products only (Wegovy, Foundayo, Zepbound KwikPen). The Lilly savings card is not usable by Medicare beneficiaries. Verify on the BCBS NC Medicare formulary.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: BCBS NC commercial plans cover Mounjaro for T2D with prior authorization. Not covered for off-label weight loss. ACA/Individual: diabetes only, PA; weight-loss GLP-1s are commonly excluded on ACA plans. Verify on the BCBS NC marketplace formulary. NC Medicaid: NC Medicaid always covered diabetes GLP-1s (including Mounjaro) — the volatile timeline concerns only the on-label weight-loss products. NC Medicaid removed weight-loss GLP-1s 10/1/2025, reinstated them 12/19/2025 (Wegovy preferred; Zepbound/Saxenda non-preferred); Mounjaro's T2D coverage was never interrupted. NC Medicaid nominal cost-share with PA. The Lilly savings card is not available to Medicaid beneficiaries. Verify tier and copay on the BCBS NC formulary or member services.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured patients without coverage (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial: plan-specific cost-share — verify on BCBS NC formulary. Lilly savings card: as low as $25/month for commercially insured patients with coverage. Medicare Part D: 25% coinsurance after deductible to the $2,100 OOP cap 2026; MFN $245/month mid-2026. NC Medicaid: nominal cost-share with PA.
Typical monthly copay once prior authorization is approved.
Bridge program
The 2026 Medicare GLP-1 Bridge ($50/month) covers weight-loss-approved products only (Wegovy, Foundayo, Zepbound KwikPen). Mounjaro is not included.
Reduced copay through the assistance program, where eligible.
All figures are estimates; actual cost-share varies by BCBS NC product and pharmacy. Confirm tier and copay on the BCBS NC formulary or by calling member services. The Lilly savings card applies only to commercially insured patients and expires 12/31/2026.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Look up Mounjaro on the BCBS NC drug list
Visit bcbsnc.com or your member portal and use the drug list (formulary) for your specific product (commercial, ACA, or Medicare Part D). Search for 'Mounjaro' or 'tirzepatide'. Confirm it is listed for type 2 diabetes (E11.x), note the tier, and check whether prior authorization is required. NC Medicaid members should confirm coverage and PA requirements with NC Medicaid or BCBS NC directly.
- 2
Have your prescriber submit the prior authorization
Your prescriber must document your confirmed T2D diagnosis, A1c of 6.5% or higher, and prior oral agent step therapy (metformin plus typically one additional agent). Ask your prescriber's office to submit a PA request to BCBS NC. Verify the specific PA criteria on the BCBS NC formulary before submission.
- 3
Call BCBS NC member services to confirm coverage and the NC Medicaid timeline
Call the number on the back of your BCBS NC card. Ask: Is Mounjaro covered for type 2 diabetes on my plan? What is my cost-share after PA? Did the NC Medicaid weight-loss GLP-1 changes affect my Mounjaro coverage? (Answer: No — Mounjaro is diabetes-only and NC Medicaid's diabetes GLP-1 coverage was never interrupted.)
Options if Blue Cross Blue Shield of North Carolina won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. Often covered with PA on BCBS NC commercial and Medicare Part D plans; may be at a more favorable tier than Mounjaro — verify on plan formulary.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative with lower list price; often preferred tier on NC commercial and Medicaid formularies — verify on plan.
Jardiance (empagliflozin)
SGLT2 inhibitor for T2D with cardiovascular benefits. Often preferred tier; may be required as step therapy before GLP-1 approval. Verify on BCBS NC formulary.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and obstructive sleep apnea — not diabetes. NC Medicaid reinstated weight-loss GLP-1s on 12/19/2025 (Wegovy preferred; Zepbound non-preferred) — verify current status on the NC Medicaid PDL. Has separate coverage from Mounjaro. Do not substitute Mounjaro for Zepbound — they are different FDA approvals.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Mounjaro is FDA-approved for type 2 diabetes only — not weight loss. BCBS NC does not cover Mounjaro for off-label weight loss under any line of business. The weight-loss tirzepatide is Zepbound, which has separate coverage. If weight loss is your goal, verify Zepbound coverage separately on the BCBS NC formulary.
No. NC Medicaid removed weight-loss GLP-1s on 10/1/2025 and reinstated them on 12/19/2025 (Wegovy preferred; Zepbound and Saxenda non-preferred). That policy change applied only to the on-label weight-loss products. Mounjaro is FDA-approved for type 2 diabetes only — NC Medicaid always covered it for T2D with PA, and that coverage was never interrupted by the weight-loss GLP-1 churn.
Mounjaro and Zepbound share the same active ingredient (tirzepatide) but have distinct FDA approvals. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. BCBS NC covers Mounjaro for diabetes with PA. Zepbound has separate coverage — including a reinstatement in NC Medicaid as non-preferred from 12/19/2025. Verify Zepbound status independently on the BCBS NC formulary.
Commercial cost-share varies — verify on the BCBS NC formulary. The Lilly savings card can reduce cost to as little as $25/month for commercially insured patients with coverage, or $499/month without (expires 12/31/2026; excludes Medicare and Medicaid). Medicare Part D: 25% coinsurance to the $2,100 OOP cap 2026; MFN $245/month mid-2026. NC Medicaid: nominal cost-share with PA.
No. The 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027) covers weight-loss-approved products only: Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss. BCBS NC Medicare Part D covers Mounjaro for diabetes under standard Part D with prior authorization and the $2,100 annual OOP cap.
Related Articles
Does BCBS North Carolina Cover Wegovy? 2026 | Curex
BCBS North Carolina: NC State Health Plan dropped weight-loss GLP-1s in 2024; NC Medicaid removed obesity coverage October 2025. Verify your specific plan.
Read moreDoes Blue Cross Blue Shield of Michigan Cover Mounjaro? | Curex
BCBS of Michigan covers Mounjaro for type 2 diabetes with PA, not weight loss. Zepbound weight-loss exclusion upheld by MI DIFS in 2025.
Read moreDoes Blue Cross Blue Shield of North Carolina Cover Ozempic? 2026 | Curex
BCBS NC covers Ozempic for type 2 diabetes with prior auth — not weight loss. NC Medicaid kept T2D coverage while removing obesity GLP-1s in Oct 2025.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield of Arizona Cover Mounjaro? | Curex
BCBS of Arizona covers Mounjaro for type 2 diabetes with prior auth — not weight loss. AZ Medicaid covers Wegovy for weight loss, but not Mounjaro.
Read moreDoes Blue Cross Blue Shield of Texas Cover Mounjaro? 2026 | Curex
BCBS of Texas covers Mounjaro for type 2 diabetes with prior auth — not weight loss. The weight-loss tirzepatide is Zepbound, covered separately.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
BCBS of North Carolina covers Mounjaro for diabetes only — the weight-loss GLP-1 coverage that NC Medicaid removed and reinstated in 2025 applies to Wegovy and Zepbound, not Mounjaro. For patients who want tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield of North Carolina before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.